Skip to main content

Table 1 Clinicopathological characteristics between the HER2- positive and HER2-negative groups

From: The volumetric-tumour histogram-based analysis of intravoxel incoherent motion and non-Gaussian diffusion MRI: association with prognostic factors in HER2-positive breast cancer

Variable

Overall (n = 148)

HER2(−) (n = 74)

HER2(+) (n = 74)

p value

Age (year)

49.68 ± 10.64

50.47 ± 11.15

49.04 ± 10.11

0.414

Diameter (cm)

3.42 ± 1.37

3.35 ± 1.20

3.48 ± 1.52

0.736

Affected side

    

 Right

64 (43.2)

30 (40.5)

34 (45.9)

0.507

 Left

84 (56.4)

44 (59.5)

40 (54.1)

 

T stage

    

 1

9 (6.0)

5 (6.7)

4 (5.4)

0.235

 2

55 (37.2)

26 (35.1)

29 (39.2)

 

 3

30 (20.3)

11 (14.9)

19 (25.7)

 

 4

54 (36.5)

32 (43.2)

22 (29.7)

 

N stage

    

 0

20 (13.5)

11 (14.9)

9 (12.1)

0.967

 1

64 (43.2)

31 (41.9)

33 (44.6)

 

 2

26 (17.6)

13 (17.5)

13 (17.6)

 

 3

38 (25.7)

19 (25.7)

19 (25.7)

 

M stage

    

 0

136 (91.9)

68 (91.9)

68 (91.9)

1.00

 1

12 (8.1)

6 (8.1)

6 (8.1)

 

cTNM

    

 1

4 (2.7)

2 (2.7)

2 (2.7)

0.685

 2

44 (29.7)

25 (33.8)

19 (25.7)

 

 3

79 (53.4)

36 (48.6)

43 (58.1)

 

 4

21 (14.2)

11 (14.9)

10 (13.5)

 

Ki 67

    
 

0.37 ± 0.20

0.35 ± 0.23

0.38 ± 0.18

0.360

  1. Numerical data are presented as the mean ± SD. Nonnumerical data are presented as the number of patients (percentage). The p value was analysed between HER2-negative group and the HER2-positive group
  2. HER2 human epidermal growth factor receptor 2, cTNM clinical TNM stage